Table 4.
No conversion | SPMS conversion | P-value | |
---|---|---|---|
N | 169 | 27 | |
Age at diagnosis | 30.8 (24.7-40.6) | 36.1 (26.4-45.1) | 0.194 |
NfL (Baseline) pg/ml | 7.9 (4.7-12.9) | 9.2 (4.5-13.7) | 0.657 |
Age at Baseline | 33.1 (26.5-42.3) | 42.6 (34.3-48.9) | 0.001 |
NfL (FU) pg/ml | 6.9 (5.0-9.2) | 10.4 (6.9-17.6) | <0.001 |
sNfL FU/BL ratio | 0.96 (0.75-1.23) | 1.16 (0.89-1.70) | 0.011 |
Age at FU | 39.1 (32.6-48.5) | 51.1 (41.0-55.6) | <0.001 |
Female | 116 (68.6) | 21 (77.8) | 0.336 |
Disease course at Baseline | 0.450 | ||
|
3 (1.8) | 1 (3.7) | |
|
166 (98.2) | 26 (96.3) | |
Smoking | 43 (35.8) | 9 (39.1) | 0.763 |
|
15.60 (±12.2) | 18.25 (±14.08) | 0.582 |
OCB positive | 148 (87.6) | 20 (74.1) | 0.063 |
Relapses | |||
|
74 (43.8) | 7 (8.6) | 0.080 |
|
108 (64.9) | 10 (37.0) | 0.008 |
|
8 (4.7) | 0 (0) | 0.248 |
EDSS | |||
|
1 (0-1.5) | 2.5 (1.0-3.5) | <0.001 |
|
1 (0-2.0) | 5.0 (3.5-6.0) | <0.001 |
Disease duration (years) | 7.4 (6.0-9.2) | 10.4 (8.2-20.2) | <0.001 |
MRI Baseline | |||
Gd-enhancement | 48 (28.4) | 8 (29.6) | 0.319 |
Gd lesion number | 0.67 (±1.80) | 1.62 (±3.86) | 0.231 |
T2 lesion number | 15.40 (±12.15) | 19.52 (±15.48) | 0.129 |
MRI FU | |||
|
6 (3.6) | 0 (0) | 1.000 |
|
0.12 (±0.78) | 0 (0) | 0.877 |
|
33 (19.5) | 6 (22.2) | 0.796 |
|
0.54 (±1.42) | 0.62 (±1.16) | 0.813 |
DMT at FU | 132 (78.1) | 18 (69.2) | 0.317 |
No. of DMTs initiated | 2 (1-3) | 3 (2-4) | 0.005 |
Disease course FU | |||
|
2 (1.2) | 0 (0) | |
|
167 (98.8) | 0 (0) | |
|
0 (0) | 27 (100.0) | |
Relapse-free progression | <0.001 | ||
|
156 (96.3) | 6 (3.7) | |
|
13 (38.2) | 21 (61.8) | |
Relapse activity - FU | |||
|
0.90 (±1.67) | 0.88 (±1.07) | 0.962 |
|
0.17 (±0.491) | 0 (±0) | 0.017 |
Data is presented as number (percentages), median (interquartile range 25th-75th percentile) or mean (± standard deviation), as appropriate. CIS: clinically isolated syndrome, DMT: disease-modifying treatment, EDSS: Expanded Disability Status Scale, Gd: Gadolinium, FU: follow-up, NfL: Neurofilament light chain, No: Number, OCB: Oligoclonal Bands, RRMS: relapsing-remitting multiple sclerosis, SPMS: secondary progressive MS.